Vaximm AG

https://www.vaximm.com

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. *

	Start	2011-01-15 existent
	Group	Vaximm (Group)
	Predecessor	Merck KGaA
	Industry	therapeutic vaccine
	Industry 2	VXM01 cancer vaccince

	Region	Basel BS
	Country	Switzerland
	Street	3 Elisabethenstr.
	City	4051 Basel BS
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Vaximm AG. (11/12/19). "Press Release: NEC and Vaximm Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines". Tokyo, Basel & Mannheim.

		Record changed: 2024-12-29